Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

microRNA-106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells.

Li H, Xu H, Shen H, Li H.

Oncol Lett. 2014 Jan;7(1):183-188. Epub 2013 Oct 29.

2.

MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.

Wu H, Xiao Z, Zhang H, Wang K, Liu W, Hao Q.

Anticancer Drugs. 2014 Aug;25(7):799-809. doi: 10.1097/CAD.0000000000000107.

PMID:
24686007
3.

MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells.

Rao YM, Shi HR, Ji M, Chen CH.

J Huazhong Univ Sci Technolog Med Sci. 2013 Aug;33(4):567-72. doi: 10.1007/s11596-013-1160-5. Epub 2013 Aug 1.

PMID:
23904379
4.

MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.

Tian J, Xu YY, Li L, Hao Q.

Am J Transl Res. 2017 Mar 15;9(3):1127-1138. eCollection 2017.

5.

MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.

Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, Wang Z.

Gynecol Oncol. 2010 Oct;119(1):125-30. doi: 10.1016/j.ygyno.2010.06.004. Epub 2010 Jul 10.

PMID:
20624637
6.

MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas.

Wang YQ, Guo RD, Guo RM, Sheng W, Yin LR.

J Cell Biochem. 2013 Jul;114(7):1464-73. doi: 10.1002/jcb.24488.

PMID:
23296900
7.

miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P.

Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13.

PMID:
21993663
8.

miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 cells.

Lou Y, Cui Z, Wang F, Yang X, Qian J.

Clin Invest Med. 2011 Oct 1;34(5):E281.

PMID:
21968270
9.

MiR-21 modulates chemosensitivity of tongue squamous cell carcinoma cells to cisplatin by targeting PDCD4.

Ren W, Wang X, Gao L, Li S, Yan X, Zhang J, Huang C, Zhang Y, Zhi K.

Mol Cell Biochem. 2014 May;390(1-2):253-62. doi: 10.1007/s11010-014-1976-8. Epub 2014 Mar 11.

PMID:
24609942
10.

Experimental study on the inhibition effect of miR-106a inhibitor on tumor growth of ovarian cancer xenografts mice.

Cai ZH, Chen LM, Liang YJ, Shi JR, You-Ju MA, Wang WM, Yang H.

Asian Pac J Trop Med. 2016 Jul;9(7):698-701. doi: 10.1016/j.apjtm.2016.05.008. Epub 2016 May 29.

11.

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance.

Yang L, Li N, Wang H, Jia X, Wang X, Luo J.

Oncol Rep. 2012 Aug;28(2):592-600. doi: 10.3892/or.2012.1823. Epub 2012 May 18.

PMID:
22614869
12.

Dysregulation of miR-106a and miR-591 confers paclitaxel resistance to ovarian cancer.

Huh JH, Kim TH, Kim K, Song JA, Jung YJ, Jeong JY, Lee MJ, Kim YK, Lee DH, An HJ.

Br J Cancer. 2013 Jul 23;109(2):452-61. doi: 10.1038/bjc.2013.305. Epub 2013 Jun 27.

13.

MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4.

Ning FL, Wang F, Li ML, Yu ZS, Hao YZ, Chen SS.

Diagn Pathol. 2014 Jul 10;9:143. doi: 10.1186/1746-1596-9-143.

14.

MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1.

Sun KX, Jiao JW, Chen S, Liu BL, Zhao Y.

J Ovarian Res. 2015 Dec 2;8:80. doi: 10.1186/s13048-015-0207-6.

15.

MicroRNA-106a confers cisplatin resistance in non-small cell lung cancer A549 cells by targeting adenosine triphosphatase-binding cassette A1.

Ma Y, Li X, Cheng S, Wei W, Li Y.

Mol Med Rep. 2015 Jan;11(1):625-32. doi: 10.3892/mmr.2014.2688. Epub 2014 Oct 17.

PMID:
25339370
16.

[Role of microRNA-21 in the proliferation and apoptosis of ovarian epithelial carcinoma cells].

Lou YH, Cui ZM, Wang FL, Yang XS.

Zhonghua Fu Chan Ke Za Zhi. 2011 Sep;46(9):684-9. Chinese.

PMID:
22176994
17.

MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.

Wu DD, Li XS, Meng XN, Yan J, Zong ZH.

Tumour Biol. 2016 Aug;37(8):10499-506. doi: 10.1007/s13277-016-4944-y. Epub 2016 Feb 5.

PMID:
26850595
18.

MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor PDCD4 and promotes cell transformation, proliferation, and metastasis in renal cell carcinoma.

Li X, Xin S, He Z, Che X, Wang J, Xiao X, Chen J, Song X.

Cell Physiol Biochem. 2014;33(6):1631-42. doi: 10.1159/000362946. Epub 2014 May 16.

19.

miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro.

Lei Y, Hu X, Li B, Peng M, Tong S, Zu X, Wang Z, Qi L, Chen M.

Med Sci Monit. 2014 Oct 7;20:1850-7. doi: 10.12659/MSM.891340.

20.

MiR-519d represses ovarian cancer cell proliferation and enhances cisplatin-mediated cytotoxicity in vitro by targeting XIAP.

Pang Y, Mao H, Shen L, Zhao Z, Liu R, Liu P.

Onco Targets Ther. 2014 Apr 23;7:587-97. doi: 10.2147/OTT.S60289. eCollection 2014.

Supplemental Content

Support Center